Erik Olshov Associate +46 10 690 04 65 +46 73 093 61 51 erik.olshov@setterwalls.se Practice areas: Mergers & Acquisitions, M&A / Equity Capital Markets / Corporate law Languages: swedish, english Office: Malmo Assistant: Ulrika Karlsson Visit Linkedin profile Profile I assist Swedish and international companies in matters regarding equity capital markets, mergers and acquisitions and corporate law. In my daily work, I assist companies with advice in conjunction with initial public offerings, new issues, corporate governance, mergers and acquisitions and general corporate law. Read more Read less To our people careercases careercases 2021-,Setterwalls2020,Lund University, LL.M.2020,Lund University, B.Sc. in Business Administration2019,Leiden University, Leiden Law School 24 Oct 2022 Setterwalls advises in the divestment of HPI Health Profile Institute 30 Sep 2022 Setterwalls advises in the divestment of Hälsomedicinskt Center 12 Jul 2022 Setterwalls has advised SynAct Pharma AB in connection with listing on Nasdaq Stockholm 12 Jul 2022 Setterwalls advises Euro Accident in the acquisition of NAKS Solution 07 Jul 2022 Setterwalls has advised Respiratorius and Arcede Pharma in connection with a rights issue and Lex Asea distribution of shares 28 Apr 2022 Setterwalls has advised SynAct Pharma AB in connection with a fully guaranteed rights issue of approximately SEK 150 million 10 Mar 2022 Setterwalls advises PPF Group in connection with an investment in Navigare Yachting 03 Dec 2021 Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 257 million 01 Dec 2021 Setterwalls has advised Resurs Holding and Solid Försäkring in connection with the Lex Asea distribution of shares and admission to trading on Nasdaq Stockholm 28 Jun 2021 Setterwalls advises Linkfire A/S in connection with listing on Nasdaq First North Premier Growth Market 21 Jun 2021 Setterwalls advises USWE Sports AB in connection with listing on Nasdaq First North Growth Market 18 Mar 2021 Setterwalls advises Ascelia Pharma in connection with SEK 200 million private placement